Background
Combined ONCAB and SAVR is the treatment of choice for concomitant
severe aortic stenosis and coronary artery disease not amenable to PCI
intervention. Extensive aortic calcification and atheromatous disease
may prohibit cardiopulmonary bypass and aortic cross clamping. In these
cases Anaortic OPCAB is a Class I (EACTS 2018) and Class IIA (AHA 2021)
indication for surgical coronary revascularization. TAVR has similar
benefits when compared to SAVR for this population (Partner 2 & 3).
Herewith we describe a case series of concomitant Anaortic OPCAB and
TAVR via the transfemoral approach for patients with coronary artery and
valve disease considered too high risk for traditional CABG and SAVR due
to severe aortic disease.